Mainz Biomed NV, a molecular genetics diagnostic company, announced the pricing of a $4.0 million follow-on offering of 2,000,000 units, each consisting of an ordinary share and Series A and B warrants. The units are priced at $2.00 each. The Series A and B warrants are exercisable at $2.00 per share, with the Series A warrants expiring five years from issuance and Series B warrants expiring either 30 days after eAArly Detect 2 study results or one year from issuance. Additionally, a Warrant Amendment Agreement reduces the strike prices of previously issued warrants to $2.00. Maxim Group LLC is the sole placement agent, with the offering expected to close around May 21, 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。